| Table 3. Countries with the highest research output on immunotherapies for RPL. | |||||||
| Country | CSP | Local citations | Average Article Citation |
CAC (%) | SCP | MCP | MCP/SCP |
|---|---|---|---|---|---|---|---|
| USA | 630 | 13454 | 48.9 | 275 (15.8) | 219 | 56 | 0.25 |
| China | 532 | 2242 | 11.4 | 197 (11.3) | 171 | 26 | 0.15 |
| United Kingdom | 480 | 9803 | 64.9 | 151 (8.7) | 119 | 32 | 0.26 |
| Japan | 329 | 2471 | 22.5 | 110 (6.3) | 104 | 6 | 0.05 |
| Italy | 298 | 1990 | 28.8 | 69 (3.8) | 54 | 15 | 0.27 |
| Canada | 267 | 2906 | 53.8 | 54 (3.1) | 40 | 14 | 0.35 |
| Spain | 250 | 1954 | 43.4 | 45 (2.6) | 37 | 8 | 0.21 |
| France | 236 | 1496 | 28.8 | 52 (2.9) | 41 | 11 | 0.26 |
| Germany | 234 | 1699 | 21.8 | 78 (4.5) | 55 | 23 | 0.41 |
| Iran | 217 | 766 | 19.6 | 39 (2.2) | 33 | 6 | 0.18 |
CSP: Country Scientific Production, total number of publications by country, considering any authorship (first author, co-author or corresponding author). CAC: corresponding author’s countries: Identifies the country of affiliation of the corresponding author (the one who leads communication with the journal). SCP: single country publication; MCP: multiple country publication.